On April 18, 2019, the Trump Administration finalized the Notice of Benefit and Payment Parameters for 2020 (NBPP). This rule will govern health insurance marketplaces and set the framework for insurance companies to propose plans and premium rates for 2020. Consumer advocates achieved several important victories in the final 2020 NBPP. Contrarily, the final rule also establishes harmful changes that will decrease access to high-quality, affordable coverage and care for families across the country.
Families USA submitted the attached letter to U.S. House of Representatives Leadership in support of H.R. 987, the Strengthening Health Care and Lowering Prescription Drug Costs Act.
Families USA, in partnership with American Academy of Family Physicians, American Benefits Council, American Federation of State, Country, and Municipal Employees, American Federation of Teachers, First Focus, and Pacific Business Group on Health, is launching Consumers First: The Alliance to Make the Health Care System Work for Everyone.
Maryland’s Easy Enrollment Health Insurance Program: An Innovative Approach to Covering the Eligible Uninsured
The threatened repeal of the Affordable Care Act (ACA), major regulatory changes that affect ACA implementation, and a likely 2020 debate over Medicare for all have understandably captured the health policy community’s attention. As a result, relatively little discussion has recently focused on a basic problem that loomed quite large in the past: enrolling the eligible uninsured into available coverage.
This postcard advertises Families USA’s Oral Health for All story collection website, which provides an avenue for people with unmet oral health needs to get involved in changing oral health policy. Through the website, people can share what they’ve experienced, become more involved in oral health policy change, and get connected with advocacy resources.
Families USA submitted comments on the Centers for Medicare and Medicaid Services Request for Information (RFI) concerning Health Care Choice Compacts. This RFI seeks to “facilitate the purchase of health insurance coverage across state lines.” We have long expressed concerns about policies that are designed to allow the sale of coverage across state lines if these policies do not include robust consumer protections.
Cheryl Fish-Parcham (Families USA), Melissa Burroughs (Families USA), Eric P. Tranby (Dentaquest Partnerhsip for Oral Health Advancement), Avery R. Brow (Dentaquest Partnership for Oral Health Advancement), Addressing Rural Seniors’ Unmet Needs For Oral Health Care, Health Affairs Blog, 5/6/2019, https://www.healthaffairs.org/do/10.1377/hblog20190501.797365/full/.
Copyright ©2015 Health Affairs by Project HOPE – The People-to-People Health Foundation, Inc.
The Centers for Medicare and Medicaid Services (CMS) recently proposed significant cutbacks to federal funding for states implementing the ACA’s Basic Health Program (BHP) option. Minnesota and New York have used this option to provide their residents with substantially more affordable coverage. Under BHP, a state can provide residents up to 200 percent of the federal poverty level (FPL) with insurance that has lower deductibles and premiums than would be charged for private insurance in a health insurance marketplace.
Patients deserve evidence-based, high-value health care rooted in the most rigorous scientific methods. However, research practices that generate our current evidence base have historically excluded a number of communities and patient perspectives. This incomplete and sometimes biased evidence base has limited effectiveness and applicability for diverse populations, and risks widening racial, ethnic, and other inequities.
Congressional committees have advanced initial measures to address prescription drug costs. However, their work to date has not focused on the significant policy changes needed to meaningfully lower drug prices. To address the drivers of excessive prescription drug prices in the United States, the Coalition for Fair Drug Prices urges Congress to enact meaningful policies that leverage the federal government’s power to negotiate drug prices.